Isolated polypeptides of CD44 and uses thereof
AssigneeYissum Research Development Company of the Hebrew University of Jerusalem
InventorsDavid Naor, Lora Eshkar-Sebban, Keren-Or Amar, Shmuel Cohen
Life of this patent
Estimating the term…
Abstract
Isolated polypeptides of CD44 are provided. Accordingly, there is provided an isolated polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-3. Also provided is an isolated end-capping modified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, wherein the modified polypeptide comprises an anti-inflammatory activity. Also provided are compositions of matter, fusion proteins and pharmaceutical compositions and their use in the treatment of inflammatory disease.
Claims13
A method of treating an inflammatory disease in a subject in need thereof, wherein said inflammatory disease is selected from the group consisting of Rheumatoid arthritis, multiple sclerosis, colitis, Crohn's disease, Alzheimer's disease and sarcoma, the method comprising administering to the subject a therapeutically effective amount of a 5 amino acid peptide consisting of SEQ ID NO:
- 1, thereby treating the inflammatory disease in the subject.
A method of treating an inflammatory disease in a subject in need thereof, wherein said inflammatory disease is selected from the group consisting of Rheumatoid arthritis, multiple sclerosis, colitis, Crohn's disease, Alzheimer's disease and sarcoma, the method comprising administering to the subject a therapeutically effective amount of a 5 amino acid peptide modified at the N- and/or C-terminus, wherein the peptide consists of SEQ ID NO:
- 1 and has an anti-inflammatory activity, thereby treating the inflammatory disease in the subject.
Dependencies are inferred from the claim text.